



CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

AFFILIÉ À  UNIVERSITÉ
LAVAL

Symptomatic Moderate AS with LV Dysfunction

Marie-Annick Clavel, DVM, PhD, FAHA
Assistant Professor - Laval University (Quebec)



Eurovalve - Palermo - 2018, April 27th

Disclosures



CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

AFFILIÉ À  UNIVERSITÉ
LAVAL

None

73-year-old symptomatic (NYHA functional class III) woman



CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

AFFILIÉ À  UNIVERSITÉ
Laval

Dyspnea and recent hospitalization for heart failure

Hypertension: SBP:135 DBP: 71mmHg

Hyperlipidemia

Coronary artery disease - Previous infarct - CABG


Known mild AS

Echocardiography




CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

AFFILIÉ À  UNIVERSITÉ
Laval



LVEF: 30%

LVOT diam: 2.2cm




Echocardiography: MG - AVA




CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

AFFILIÉ À UNIVERSITÉ LAVAL



SV: 44ml



Vpeak: 2.32m/s
MG: 12mmHg



AVA: 0.94cm²
AVAi: 0.55cm²/m²

Dobutamine stress echo: Peak



CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

AFFILIÉ À  UNIVERSITÉ
LAVAL



SV: 66ml

Vpeak: 2.66m/s

MG: 19mmHg

Moderate AS

AVA: 1.12cm²

AVAi: 0.66cm²/m²

Qmean: 259ml/s

What would you do?



CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

AFFILIÉ À  UNIVERSITÉ LAVAL

- 1- Treat with ACE inhibitor  and betablockers?
Already on both
- 2 - Add mineralocorticoid receptor antagonist?
Already on Spironolactone
- 3 - ~~QTc~~  QRS<130ms
- 4 - Ivabradine?  HR<70
- 5 - Left Ventricular assist device?
- 6 - Heart transplant?

Outcome of Patients with Moderate AS and Low LVEF




CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC


AFFILIÉ À
 UNIVERSITÉ
LAVAL

Retrospective 3-center study of 305 patients with moderate AS and LVEF<50%

Death, AVR or HF hospitalization



CENTRAL ILLUSTRATION: Moderate Aortic Stenosis and LV Systolic Dysfunction



Prognostic Implications at 4-year follow-up:

- All-cause death or hospitalization for heart failure-48%
- All-cause death-36%
- Aortic valve replacement-24%
- Hospitalization for heart failure-27%

Factors Associated with Worse Prognosis:

- Male sex
- NYHA functional class III or IV
- Higher transaortic velocities

Future Treatment Option:

- Early transcatheter aortic valve replacement; to be investigated in the randomized TAVR-UNLOAD trial.

van Gils, L. et al. J Am Coll Cardiol. 2017;69(19):2383-92.


Van Gils et al. JACC 2017

Predictors of Mortality in Patients with Low-LVEF, Low-Flow, Low -Gradient AS Treated Medically - TOPAS Study




CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

AFFILIÉ À UNIVERSITÉ LAVAL






CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC



**PRESERVED LV
FUNCTION**



GOOD OUTCOME

**MODERATE AS
(SEVERE AS)**







CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

AFFILIÉ À  UNIVERSITÉ
Laval

LV DYSFUNCTION
(Systolic or Diastolic)



**HEART FAILURE
POOR OUTCOME**



MODERATE AS



Why Transfemoral TAVR would be a good option in Moderate AS



CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

AFFILIÉ À  UNIVERSITÉ LAVAL

- Patients with **moderate AS** have **low gradient** at baseline
- Provide large valve EOAs and low gradients: greater potential for significant **hemodynamic benefit**
- Low rates of **paravalvular regurgitation**: more impact in HF/LVH patients
- **Transfemoral TAVR** and under conscious sedation will be feasible in the vast majority of patients with moderate AS and HF





CENTRE DE RECHERCHE
INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

AFFILIÉ À  UNIVERSITÉ
LAVAL

DISCUSSION.....